Morgan Stanley Sticks to Its Hold Rating for Insmed (INSM)
Morgan Stanley analyst Maxwell Skor maintained a Hold rating on Insmed today and set a price target of $162.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Skor covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Pharvaris, and Insmed. According to TipRanks, Skor has an average return of 23.6% and a 67.95% success rate on recommended stocks.
In addition to Morgan Stanley, Insmed also received a Hold from TipRanks – OpenAI’s OpenAI Biotechnology in a report issued today. However, on the same day, TipRanks – Google upgraded Insmed (NASDAQ: INSM) to a Buy.
Based on Insmed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $142.34 million and a GAAP net loss of $370.02 million. In comparison, last year the company earned a revenue of $93.43 million and had a GAAP net loss of $220.52 million
Based on the recent corporate insider activity of 146 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, William Lewis, the Chair and CEO of INSM sold 9,676.00 shares for a total of $1,683,949.58.
Read More on INSM:
